Practice Changing Updates in Gastro-intestinal Oncology 2018

Abstract

In this article the pivotal presentations at major conferences for gastro-intestinal cancers have been discussed. This year the presentations on Colon, pancreas and hepatocellular cancers have practice changing potential.  For metastatic colorectal cancer, fluoropyramidine plus panitumumab combination should be the preferred maintenance option for patients who have stopped oxaliplatin. The cytoreductive surgery alone showed satisfactory survival outcomes in colorectal cancer patients with peritoneal carcinomatosis. Dose escalation of regorafenib showed better clinical outcomes than standard dosing regimen. Adjuvant FOLFIRINOX is the new option for selected resected pancreatic cancer patients. Neoadjuvant treatment is the new paradigm for borderline and resectable pancreatic cancer patients. Several options for advanced hepatocellular cancers now available and optimal sequencing could be challenging. The following selected presentations highlights the conference updates in gastrointestinal malignancies.